Monoclonal antibody techniques. 50 years of development

Monoclonal antibodies are widely used in all fields of biology and medicine. The emergence and development of the technology for their production revolutionized immunology and allowed the creation of not only new diagnostic methods, but also many effective drugs. The purpose of our review is to analyze and summarize relevant data concerning the technology of obtaining monoclonal antibodies. We have analyzed information from 70 modern literary sources devoted to various methods of obtaining them. In this review, we tried to cover the entire range of methods used to obtain monoclonal antibodies today.

[1]  I. Martínez,et al.  Production and characterization of monoclonal antibodies for the detection of the hepatitis C core antigen , 2023, Frontiers in molecular biosciences.

[2]  Yang Zhang Evolution of phage display libraries for therapeutic antibody discovery , 2023, mAbs.

[3]  N. Austriaco Yeast oral vaccines against infectious diseases , 2023, Frontiers in Microbiology.

[4]  Atsumi Sakaguchi,et al.  Rapid, simple, and effective strategy to produce monoclonal antibodies targeting protein structures using hybridoma technology , 2023, Journal of Biological Engineering.

[5]  K. Schuebel,et al.  Convergent antibody responses are associated with broad neutralization of hepatitis C virus , 2023, Frontiers in Immunology.

[6]  V. Srivastava,et al.  Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery , 2023, Vaccines.

[7]  A. Buisman,et al.  A synthetic human 3D in vitro lymphoid model enhancing B-cell survival and functional differentiation , 2022, iScience.

[8]  A. C. de Freitas,et al.  Standardization and Key Aspects of the Development of Whole Yeast Cell Vaccines , 2022, Pharmaceutics.

[9]  A. K. Ryabko,et al.  Optimization of Electrofusion Parameters for Producing Hybridomas Synthesizing Human Monoclonal Antibodies , 2022, Biotekhnologiya.

[10]  M. Imamura,et al.  Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants , 2022, PloS one.

[11]  P. Dalby,et al.  The global landscape of approved antibody therapies , 2022, Antibody therapeutics.

[12]  G. Pantaleo,et al.  Antibodies to combat viral infections: development strategies and progress , 2022, Nature Reviews Drug Discovery.

[13]  T. Yasui,et al.  Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin , 2022, Pharmacology & Therapeutics.

[14]  Oliver J. Dressler,et al.  High-throughput single-cell antibody secretion quantification and enrichment using droplet microfluidics-based FRET assay , 2022, iScience.

[15]  Y. Sado,et al.  An improved iliac lymph node method for production of monoclonal antibodies , 2021, Development, growth & differentiation.

[16]  M. Tomita,et al.  Class-Switching of B Lymphocytes by DNA and Cell Immunization for Stereospecific Monoclonal Antibodies against Native GPCR , 2021, Immuno.

[17]  A. Oxenius,et al.  Single B cell technologies for monoclonal antibody discovery. , 2021, Trends in immunology.

[18]  S. Pambudi,et al.  Humoral and cellular immunity in mice immunized with whole recombinant yeast expressing complex NS2B/NS3 protein of dengue serotype 3 , 2021, IOP Conference Series: Earth and Environmental Science.

[19]  Elena Ivanova Yeasts in nanotechnology-enabled oral vaccine and gene delivery , 2021, Bioengineered.

[20]  A. H. Laustsen,et al.  Animal Immunization, in Vitro Display Technologies, and Machine Learning for Antibody Discovery. , 2021, Trends in biotechnology.

[21]  S. Krah,et al.  Antibody display technologies: selecting the cream of the crop , 2021, Biological chemistry.

[22]  R. Aguiar,et al.  Hybridoma technology: is it still useful? , 2021, Current research in immunology.

[23]  A. Solonin,et al.  A simple method to purify recombinant HCV core protein expressed in Pichia pastoris for obtaining virus-like particles and producing monoclonal antibodies. , 2021, Protein expression and purification.

[24]  Aaron M. Seese,et al.  Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies , 2020, Journal of Immunological Methods.

[25]  C. Sharma,et al.  Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives , 2020, International Immunopharmacology.

[26]  R. Rappuoli,et al.  Editorial: Reverse Vaccinology , 2019, Front. Immunol..

[27]  В. Н. Каркищенко,et al.  ТРАНСГЕННЫЕ И НОКАУТНЫЕ КРОЛИКИ В БИОМЕДИЦИНЕ И ГЕНОТЕРАПИИ. CRISPR/CAS9-ТЕХНОЛОГИИ (ОБЗОР) , 2019 .

[28]  Yu. N. Tarakanova,et al.  Твердофазный иммуноферментный анализ: история, теория и практическое использование , 2019 .

[29]  Piyush Kumar,et al.  Yeast-based vaccines: New perspective in vaccine development and application. , 2019, FEMS yeast research.

[30]  E. Kashuba,et al.  The Immunogenicity in Mice of HCV Core Delivered as DNA Is Modulated by Its Capacity to Induce Oxidative Stress and Oxidative Stress Response , 2019, Cells.

[31]  Eleanor Barnes,et al.  Approaches, Progress, and Challenges to Hepatitis C Vaccine Development , 2019, Gastroenterology.

[32]  Виталий Васильевич Зверев,et al.  РЕКОМБИНАНТНЫЕ АНТИТЕЛА В ПРОТИВОВИРУСНОЙ ТЕРАПИИ: ДОСТИЖЕНИЯ И ПЕРСПЕКТИВЫ , 2018 .

[33]  Valerie J Kinchen,et al.  Defining Breadth of Hepatitis C Virus Neutralization , 2018, Front. Immunol..

[34]  Valerie J Kinchen,et al.  Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? , 2018, Trends in microbiology.

[35]  Y. Jang,et al.  Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate , 2018, Microbial Cell Factories.

[36]  J. Ball,et al.  A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo , 2017, Antiviral research.

[37]  Christoph A Merten,et al.  Microfluidic single-cell technology in immunology and antibody screening. , 2017, Molecular aspects of medicine.

[38]  H. Kang,et al.  Oral vaccination through voluntary consumption of the convict grouper Epinephelus septemfasciatus with yeast producing the capsid protein of red-spotted grouper nervous necrosis virus. , 2017, Veterinary microbiology.

[39]  T. Steele Life begins at forty – hybridomas: ageing technology holds promise for future drug discoveries , 2016 .

[40]  S. El-Kafrawy,et al.  Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. , 2015, World journal of hepatology.

[41]  Burak Dura,et al.  Deformability-based microfluidic cell pairing and fusion. , 2014, Lab on a chip.

[42]  Y. Lee,et al.  Oral immunization with whole yeast producing viral capsid antigen provokes a stronger humoral immune response than purified viral capsid antigen , 2014, Letters in applied microbiology.

[43]  Simon J. Henderson,et al.  Monoclonal antibody therapeutics: history and future. , 2012, Current opinion in pharmacology.

[44]  Christoph A. Merten,et al.  Functional single-cell hybridoma screening using droplet-based microfluidics , 2012, Proceedings of the National Academy of Sciences.

[45]  Andressa Ardiani,et al.  Vaccines based on whole recombinant Saccharomyces cerevisiae cells. , 2010, FEMS yeast research.

[46]  Andreas Radbruch,et al.  Generation of stable monoclonal antibody-producing BCR+ human memory B cells by genetic programming , 2009, Nature Medicine.

[47]  A. Tarr,et al.  Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. , 2007, The Journal of general virology.

[48]  S. Emerson,et al.  Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity , 2005, Hepatology.

[49]  Fatıma YÜcel,et al.  Development of mouse hybridomas by fusion of myeloma cells with lymphocytes derived from spleen, lymph node, and bone marrow. , 2003, Hybridoma and hybridomics.

[50]  A. Prilipov,et al.  IL-21/CD40L stimulation of human B-lymphocytes in vitro and their characteristics , 2020 .

[51]  G. Winter,et al.  Making antibodies by phage display technology. , 1994, Annual review of immunology.